Patents by Inventor Anandan Palani

Anandan Palani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
    Publication number: 20200270325
    Abstract: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Application
    Filed: September 21, 2018
    Publication date: August 27, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Qiaolin Deng, Chunhui Huang, Yuping Zhu, Elisabetta Bianchi, Federica Orvieto
  • Co-agonists of the glucagon and GLP-1 receptors
    Patent number: 10493125
    Abstract: Co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: December 3, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Paul E. Carrington, Antonello Pessi, Armin Lahm, Elisabetta Bianchi, Anna Demartis
  • LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
    Publication number: 20190338008
    Abstract: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Application
    Filed: October 21, 2016
    Publication date: November 7, 2019
    Inventors: Anandan Palani, Ravi Nargund, Paul E. Carrington, Tomi Sawyer, Qiaolin Deng, Antonello Pessi, Elisabetta Bianchi, Federica Orvieto
  • Co-agonists of the glucagon and GLP-1 receptors
    Patent number: 10413593
    Abstract: Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: September 17, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Elisabetta Bianchi, Paul E. Carrington, Qiaolin Deng, Ravi Nargund, Federica Orvieto, Anandan Palani, Antonello Pessi, Thomas Joseph Tucker, Chengwei Wu
  • INSULIN DIMER-INCRETIN CONJUGATES
    Publication number: 20190192675
    Abstract: Insulin dimers conjugated to peptides having at least one incretin activity are disclosed.
    Type: Application
    Filed: April 21, 2017
    Publication date: June 27, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anandan PALANI, ZhiQiang YANG, Lin YAN, Songnian LIN, Pei HUO, Ravi NARGUND
  • INSULIN-INCRETIN CONJUGATES
    Publication number: 20190175744
    Abstract: Insulin-incretin conjugates comprising a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, and/or the gastric inhibitory protein (GIP) receptor conjugated to an insulin molecule having agonist activity at the insulin receptor and use of the conjugates for treatment of metabolic diseases, for example, Type 2 diabetes, are described.
    Type: Application
    Filed: March 13, 2017
    Publication date: June 13, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Chunhui Huang, Zhiqiang Yang, Lin Yan, Songnian Lin, Pei Huo, Qiaolin Deng, Elisabetta Bianchi, Federica Orvieto
  • CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
    Publication number: 20180339017
    Abstract: Co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Application
    Filed: December 5, 2016
    Publication date: November 29, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Paul E. Carrington, Antonello Pessi, Armin Lahm, Elisabetta Bianchi, Anna Demartis
  • NK 1 ANTAGONISTS
    Publication number: 20180215729
    Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 2, 2018
    Inventors: Anandan PALANI, Xianhai HUANG, Dong XIAO, Sunil PALIWAL, Hon-Chung TSUI, Michelle Laci WROBLESKI, Ashwin U. RAO, Cheng WANG, Sapna S. SHAH, Neng-Yang SHIH
  • NKantagonists
    Patent number: 9969711
    Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: May 15, 2018
    Assignee: OPKO Health, Inc.
    Inventors: Anandan Palani, Xianhai Huang, Dong Xiao, Sunil Paliwal, Hon-Chung Tsui, Michelle Laci Wrobleski, Ashwin U. Rao, Cheng Wang, Sapna S. Shah, Neng-Yang Shih
  • CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
    Publication number: 20170360893
    Abstract: Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity
    Type: Application
    Filed: October 22, 2015
    Publication date: December 21, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Elisabetta Bianchi, Paul E. Carrington, Qiaolin Deng, Ravi Nargund, Federica Orvieto, Anandan Palani, Antonello Pessi, Thomas Joseph Tucker, Chengwei Wu
  • NK1 ANTAGONISTS
    Publication number: 20170283434
    Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
    Type: Application
    Filed: June 23, 2017
    Publication date: October 5, 2017
    Inventors: Sunil Paliwal, Gregory A. Reichard, Cheng Wang, Dong Xiao, Hon-Chung Tsui, Neng-Yang Shih, Juan D. Arredondo, Michelle Laci Wrobleski, Anandan Palani
  • Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use
    Patent number: 9745324
    Abstract: In its many embodiments, the present invention provides certain iminothiadiazepane dioxide compounds, including compounds Formula (I): or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein RN, R1A, R1B, R2, R3, R4, ring A, RA, m, -L1-, and RL are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and may be useful for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: August 29, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Xing Dai, Jared N. Cumming, Jack D. Scott, Hong Liu, Anandan Palani
  • NKantagonists
    Patent number: 9688693
    Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: June 27, 2017
    Assignee: OPKO Health, Inc.
    Inventors: Sunil Paliwal, Gregory A. Reichard, Cheng Wang, Dong Xiao, Hon-Chung Tsui, Neng-Yang Shih, Juan D. Arredondo, Michelle Laci Wrobleski, Anandan Palani
  • Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
    Patent number: 9573939
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: February 21, 2017
    Assignees: Merck Sharp & Dohme Corp., MSD Italia SRL
    Inventors: Casey C. McComas, Nigel J. Liverton, Joerg Habermann, Uwe Koch, Frank Narjes, Peng Li, Xuanjia Peng, Richard Soll, Hao Wu, Anandan Palani, Xing Dai, Hong Liu, Shuwen He, Qun Dang
  • Iminothiadiazepane Dioxide Compounds as BACE Inhibitors, Compositions, and Their Use
    Publication number: 20170037056
    Abstract: In its many embodiments, the present invention provides certain iminothiadiazepane dioxide compounds, including compounds Formula (I): or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein RN, R1A, R1B, R2, R3, R4, ring A, RA, m, -L1-, and RL are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and may be useful for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Application
    Filed: December 16, 2014
    Publication date: February 9, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Xing Dai, Jared N. Cumming, Jack D. Scott, Hong Liu, Anandan Palani
  • NK 1 ANTAGONISTS
    Publication number: 20170029403
    Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
    Type: Application
    Filed: October 14, 2016
    Publication date: February 2, 2017
    Inventors: Anandan Palani, Xianhai Huang, Dong Xiao, Sunil Paliwal, Hon-Chung Tsui, Michelle Laci Wrobleski, Ashwin U. Rao, Cheng Wang, Sapna S. Shah, Neng-Yang Shih
  • Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C
    Patent number: 9549921
    Abstract: The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: January 24, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Shuwen He, Zhong Lai, Xing Dai, Dong Xiao, Clare London, Nicolas Zorn, Ravi Nargund, Anandan Palani, Casey C. McComas, Peng Li, Xuanjia Peng, Richard Soll
  • Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
    Patent number: 9549917
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: January 24, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Casey C. McComas, Nigel J. Liverton, Joerg Habermann, Uwe Koch, Frank Narjes, Peng Li, Xuanjia Peng, Richard Soll, Hao Wu, Anandan Palani, Xing Dai, Hong Liu, Shuwen He, Zhong Lai, Qun Dang, Nicolas Zorn
  • Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C
    Patent number: 9493461
    Abstract: The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: November 15, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Xing Dai, Hong Liu, Anandan Palani, Shuwen He, Zhong Lai, Ravi Nargund, Karen Marcantonio, Dong Xiao, Linda L. Brockunier, Nicolas Zorn, Qun Dang, Xuanjia Peng, Peng Li
  • NKantagonists
    Patent number: 9469629
    Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: October 18, 2016
    Assignee: OPKO Health, Inc.
    Inventors: Anandan Palani, Xianhai Huang, Dong Xiao, Sunil Paliwal, Hon-Chung Tsui, Michelle Laci Wrobleski, Ashwin U. Rao, Cheng Wang, Sapna S. Shah, Neng-Yang Shih